User profiles for Eric Hsi
 | Eric HsiMayo Clinic Rochester Verified email at mayo.edu Cited by 30686 |
[HTML][HTML] Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …
Plasma cell myeloma and related neoplasms
Session 1 of the 2009 Workshop of the Society for Hematopathology/European Association
of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report …
of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report …
T-lymphoblastic leukemia/lymphoma
MJ You, LJ Medeiros, ED Hsi - American journal of clinical …, 2015 - academic.oup.com
Objectives To review important concepts from the 2013 Society for Hematopathology/European
Association for Haematopathology Workshop session on T-acute lymphoblastic leukemia…
Association for Haematopathology Workshop session on T-acute lymphoblastic leukemia…
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
…, JR Goodlad, JG Gribben, ED Hsi… - Blood, The Journal …, 2022 - ashpublications.org
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms
in 1994, subsequent updates of the classification of lymphoid neoplasms have been …
in 1994, subsequent updates of the classification of lymphoid neoplasms have been …
[PDF][PDF] Genetic and functional drivers of diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
Purpose Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's
lymphoma with no accepted standard of care. This study evaluated the efficacy and …
lymphoma with no accepted standard of care. This study evaluated the efficacy and …
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on gene …
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on gene …
The genetic landscape of mutations in Burkitt lymphoma
Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other
genetic mutations to the disease is largely unknown. Here, we describe the first completely …
genetic mutations to the disease is largely unknown. Here, we describe the first completely …
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
ED Hsi, R Steinle, B Balasa, S Szmania… - Clinical Cancer …, 2008 - AACR
Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3
subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously associated …
subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously associated …
Genetic heterogeneity of diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults. The
disease exhibits a striking heterogeneity in gene expression profiles and clinical outcomes, …
disease exhibits a striking heterogeneity in gene expression profiles and clinical outcomes, …